Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry

Sonova rechargeable CROS transmitter benefit study

Also known as: Sonova CROS Transmitter Benefit Study, BiCROS fitting, CROS baseline, SRF-377, NCT05106413

Sonova AG

Primary source

Company

Sonova AG

Program Type

Software/Neurotech

Modality

Hearing Aid/Software

Stage

Interventional/NA

Status

Discontinued

Target Gene

—

Route / Mode

External CROS/BiCROS hearing device system

Confidence

84%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-09

Geography

Switzerland

Population

adult, unilateral-hearing-loss, hearing-aid-user, cros

Trial IDs

Mechanism

Rechargeable contralateral routing of signals transmitter evaluated with compatible hearing devices for adults with asymmetric or unilateral hearing loss.

Indications

Hearing Loss Unilateral Hearing Loss

Notes

Verified as a Sonova-sponsored CROS/BiCROS device-system benefit study. It was terminated early due to recruitment issues, so this remains a study-level record rather than a standalone product record.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, company, stage, status, route, indications, populationTags...

IDs: NCT05106413, SRF-377

Open

Key Events

2021-10-26

Sonova CROS transmitter study started

2022-04-15

ClinicalTrials.gov update lists early termination due to recruiting issues

Clinical Trials (1)